- Home
- GCBC vs TRVI Comparison
GCBC vs TRVI Comparison
Compare GCBC & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCBC
- TRVI
- Stock Information
- Founded
- GCBC 1889
- TRVI 2011
- Country
- GCBC United States
- TRVI United States
- Employees
- GCBC N/A
- TRVI N/A
- Industry
- GCBC Banks
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- GCBC Finance
- TRVI Health Care
- Exchange
- GCBC Nasdaq
- TRVI Nasdaq
- Market Cap
- GCBC 364.4M
- TRVI 383.4M
- IPO Year
- GCBC 1998
- TRVI 2019
- Fundamental
- Price
- GCBC $21.43
- TRVI $6.07
- Analyst Decision
- GCBC
- TRVI Strong Buy
- Analyst Count
- GCBC 0
- TRVI 8
- Target Price
- GCBC N/A
- TRVI $17.56
- AVG Volume (30 Days)
- GCBC 66.3K
- TRVI 1.5M
- Earning Date
- GCBC 04-29-2025
- TRVI 05-06-2025
- Dividend Yield
- GCBC 1.69%
- TRVI N/A
- EPS Growth
- GCBC N/A
- TRVI N/A
- EPS
- GCBC 1.54
- TRVI N/A
- Revenue
- GCBC $65,848,000.00
- TRVI N/A
- Revenue This Year
- GCBC N/A
- TRVI N/A
- Revenue Next Year
- GCBC N/A
- TRVI N/A
- P/E Ratio
- GCBC $13.47
- TRVI N/A
- Revenue Growth
- GCBC N/A
- TRVI N/A
- 52 Week Low
- GCBC $20.00
- TRVI $2.30
- 52 Week High
- GCBC $37.25
- TRVI $7.39
- Technical
- Relative Strength Index (RSI)
- GCBC 38.89
- TRVI 54.43
- Support Level
- GCBC $20.62
- TRVI $4.85
- Resistance Level
- GCBC $21.95
- TRVI $6.39
- Average True Range (ATR)
- GCBC 1.26
- TRVI 0.46
- MACD
- GCBC 0.04
- TRVI -0.02
- Stochastic Oscillator
- GCBC 40.40
- TRVI 78.71
About GCBC Greene County Bancorp Inc.
Greene County Bancorp Inc is a holding firm. Its primary business involves overseeing and directing the business of The Bank of Greene County and monitoring its cash position. Through its directly and indirectly owned subsidiaries, the company engages in attracting retail deposits, along with funds generated from operations and borrowings, predominantly in one to four-family residential mortgage loans, commercial real estate mortgage loans, consumer loans, home equity loans, and commercial business loans. It also serves local municipalities' banking needs and operates a real estate investment trust.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.